Log in

NASDAQ:PDLIPDL BioPharma Stock Price, Forecast & News

$3.19
-0.05 (-1.54 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.17
Now: $3.19
$3.27
50-Day Range
$2.94
MA: $3.24
$3.63
52-Week Range
$2.06
Now: $3.19
$3.86
Volume730,342 shs
Average Volume956,178 shs
Market Capitalization$371.79 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84
PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in the United States, Europe, and internationally. The company operates in three segments: Pharmaceutical, Medical Devices, and Income Generating Assets. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures, markets, and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Read More
PDL BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.97 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PDLI
CUSIP69329Y10
Phone775-832-8500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.76 million
Cash Flow$0.44 per share
Book Value$5.20 per share

Profitability

Net Income$-70,410,000.00

Miscellaneous

Employees105
Market Cap$371.79 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.

PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions

How has PDL BioPharma's stock been impacted by COVID-19 (Coronavirus)?

PDL BioPharma's stock was trading at $3.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PDLI shares have increased by 3.9% and is now trading at $3.19. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PDL BioPharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for PDL BioPharma.

When is PDL BioPharma's next earnings date?

PDL BioPharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for PDL BioPharma.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.31. The biotechnology company had revenue of $6 million for the quarter. View PDL BioPharma's earnings history.

How will PDL BioPharma's stock buyback program work?

PDL BioPharma announced that its board has initiated a share buyback plan on Monday, September 24th 2018, which permits the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 27.3% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's management believes its shares are undervalued.

What price target have analysts set for PDLI?

1 analysts have issued 1-year price targets for PDL BioPharma's shares. Their forecasts range from $3.00 to $3.00. On average, they expect PDL BioPharma's stock price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 6.0%. View analysts' price targets for PDL BioPharma.

Has PDL BioPharma been receiving favorable news coverage?

Media coverage about PDLI stock has been trending very positive on Thursday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. PDL BioPharma earned a news impact score of 4.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutPDL BioPharma.

Are investors shorting PDL BioPharma?

PDL BioPharma saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 6,750,000 shares, an increase of 13.4% from the April 15th total of 5,950,000 shares. Based on an average daily trading volume, of 1,400,000 shares, the short-interest ratio is presently 4.8 days. Currently, 5.7% of the company's stock are short sold. View PDL BioPharma's Current Options Chain.

Who are some of PDL BioPharma's key competitors?

What other stocks do shareholders of PDL BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), Canopy Growth (CGC), Opko Health (OPK), Advanced Micro Devices (AMD), Novavax (NVAX), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Bank of America (BAC), Cara Therapeutics (CARA) and Gilead Sciences (GILD).

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the following people:
  • Mr. Dominique P. Monnet, CEO, Pres & Director (Age 58)
  • Mr. Peter S. Garcia, VP & CFO (Age 57)
  • Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 55)
  • Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

Who are PDL BioPharma's major shareholders?

PDL BioPharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.06%), Silver Point Capital L.P. (4.20%), Connor Clark & Lunn Investment Management Ltd. (3.19%), Engine Capital Management LP (2.71%), State Street Corp (2.69%) and Geode Capital Management LLC (1.46%). View institutional ownership trends for PDL BioPharma.

Which institutional investors are selling PDL BioPharma stock?

PDLI stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Engine Capital Management LP, Morgan Stanley, WINTON GROUP Ltd, AQR Capital Management LLC, BlackRock Inc., Russell Investments Group Ltd., and Invesco Ltd.. View insider buying and selling activity for PDL BioPharma.

Which institutional investors are buying PDL BioPharma stock?

PDLI stock was purchased by a variety of institutional investors in the last quarter, including Silver Point Capital L.P., Madison Avenue Partners LP, Kestrel Investment Management Corp, Fuller & Thaler Asset Management Inc., West Family Investments Inc., Hancock Whitney Corp, Geode Capital Management LLC, and GSA Capital Partners LLP. View insider buying and selling activity for PDL BioPharma.

How do I buy shares of PDL BioPharma?

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDLI stock can currently be purchased for approximately $3.19.

How big of a company is PDL BioPharma?

PDL BioPharma has a market capitalization of $371.79 million and generates $54.76 million in revenue each year. The biotechnology company earns $-70,410,000.00 in net income (profit) each year or $0.28 on an earnings per share basis. PDL BioPharma employs 105 workers across the globe.

What is PDL BioPharma's official website?

The official website for PDL BioPharma is www.pdl.com.

How can I contact PDL BioPharma?

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.